Hospital Buyer

Abbott Laboratories received marketing clearance for the company’s most up-to-date iteration of the XIENCE stent, the XIENCE V Everolimus Eluting Coronary Stent system. The device is indicated to treat patients with coronary artery disease.

The new XIENCE releases everolimus in a controlled manner. The stent is used to open either blocked or narrowing arteries. The combination of these two features reduces the likelihood that the artery will again narrow. The stent will be available in two designs, an over the wire (OTW) delivery system, as well as a Rapid Exchange (RX) system.

The XIENCE V was manufactured using the Abbott bare metal stent, the Multi-Link vision. This stent profile fosters improvements through simplification of device implantation.

Data available on the efficacy of the device indicates that such is superior to the Taxus paclitaxel eluting stent system available from Boston Scientific. This is the only stent available that has been proven superior. This is the only drug eluting stent on the market that has been demonstrated superior to the Taxus.

The system was particularly created to improve upon both the efficacy and safety of the earlier generations of drug eluting stents. The company published efficacy data about the product in the news release that described approval of the XIENCE V.

July 2, 2008 Related topics: Product Launches, Product Approval & Certification, Cardiology